PPD, Inc. (PPD) |
| 47.28 0 (0%) 04-24 15:47 |
| Open: | 47.32 |
| High: | 47.4 |
| Low: | 47.24 |
| Volume: | 1,868,187 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 153.23 |
| Resistance 1: | 146.87 |
| Pivot price: | 145.16 |
| Support 1: | 136.59 |
| Support 2: | 113.64 |
| 52w High: | 47.41 |
| 52w Low: | 31.54 |
PPD, Inc. delivers a full spectrum of drug development services internationally, primarily catering to the biopharmaceutical industry. The company structures its operations across two core divisions: Clinical Development Services and Laboratory Services. Under its Clinical Development arm, PPD provides a diverse range of support, including initial product strategy and advisory services, early-stage development, end-to-end management of clinical trials from Phase II through Phase IV, techniques for accelerated patient recruitment, assistance with pre- and post-market approval processes, and various medical communication solutions. Furthermore, its Laboratory Services segment encompasses specialized capabilities such as bioanalytical analysis, biomarker identification, vaccine science expertise, adherence to Good Manufacturing Practice (GMP) guidelines, and centralized laboratory testing. The firm's extensive client base reaches beyond pharmaceutical and biotechnology companies to include manufacturers of medical devices, governmental organizations, and other participants throughout the industry. PPD, Inc. was established in 1985 and maintains its corporate headquarters in Wilmington, North Carolina.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 02 Apr 2026
Textron Systems Awarded $450m Advanced Reconnaissance Vehicle (ARV) Pre-Production Development (PPD) Award By U.S. Marine Corps - Textron Inc. - Investor Relations
Thu, 02 Apr 2026
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld News
Wed, 25 Mar 2026
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Registry - Contract Pharma
Tue, 24 Mar 2026
Postpartum depression isn’t just a private struggle. It can show up at work, too - Fast Company
Tue, 16 Dec 2025
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Thu, 09 Dec 2021
Thermo Fisher acquires clinical research services provider PPD for $17.4bn - Pharmaceutical Technology
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |